Pfizer claims its COVID-19 vaccine to be “highly effective” against the variant of COVID-19 virus prevalent in India :
On 26 May 2021, Pfizer announced that its COVID-19 vaccine is “highly effective” against the variant that is prevalent in India. It also presented data to the Indian government to prove the vaccine’s effectiveness on people of Indian ethnicity. The company added that it has repeatedly sought fast-track approval of its vaccine in India.
In the third week of May 2021, Pfizer told the government that its vaccine is suitable for all aged above 12 years and can be stored at 2 to 8 degrees. It also revealed its willingness to offer 5 crore shots to India between July 2021 and October 2021.
The pharma giant has, however, sought certain relaxations before supplying the vaccines, especially indemnification.
The Indian government has agreed to jointly work together with Pfizer to accelerate the approval of the company’s vaccine in India. It plans to address the three key issues in this regard. These are procurement of the vaccines through the central government pathway, indemnity and liability, and regulatory requirements for post-approval bridging studies.
At present, two vaccines are being used in India. These are Covishield manufactured by the SII and Covaxin of Bharat Biotech. Russian-made Sputnik V is being used at a small scale to inoculate the population. All three jabs are approved for use in people above 18 years of age.
Pfizer claims its COVID-19 vaccine as “highly effective”
The US pharma firm has stated that India should on the 44 authorizations, including WHO approval to grant EUA for its vaccine in India. It further opinioned that India should not seek a local PSA study.
Based on the data collected by UK’s PHE, Pfizer’s vaccine reveals 87.9 % effectiveness against the B.1.617.2 variant, which is the most reported in India. An observational study that ended on 22 May 2021 revealed this.
Pfizer also stated that around 26 % of the participants of this study were of Indian or British Indian ethnicity. This study also included people of Bangladeshi (1.4%), Pakistani (5.9%), and other Asian backgrounds (5.7%). The observed effectiveness was the same in the participants belonging to these backgrounds as well.
- 1. Serum Institute of India
- 2. World Health Organization
- 3. Emergency Use Authorization
- 4. Post Approval Commitment
- 5. Public Health England
- Monthly Update- pharma News July 2021
- Moderna collaborates with Thermo Fischer Scientific
- Bamlanivimab and Etesevimab: EUA in India
- JB Chemicals launches NOSMOK nicotine lozenges
- 2-DG: anti-COVID-19 by the INMAS
- GSK and Vir Biotechnology plan to launch Sotrovimab
- USFDA approves Gland Pharma’s Foscarnet
- Gilead delivers Amphotericin B to India
- Monthly Update- pharma News June 2021
- Zydus seeks DCGI’s approval for COVID-19 biological therapy
- Zydus and TLC to commercialize AmphoTLC in India
- Sun Pharma recalls Metformin tablets from the US market
- Pfizer – BioNTech pledge to supply 2 billion doses
- Johnson & Johnson COVID Vaccine update
- Jubilant, Sun, and Lupin initiated products recall
- USFDA approves Gland Pharma’s Foscarnet Injection
- NMPA approves Tagrisso as an adjuvant therapy in early–stage lung cancer.
- Vaccination drive in South Korea
- VAV Lifesciences: mRNA – based vaccine supply chain
- Remdesivir with NDDS: Jubilant seeks approval
- J&J COVID vaccine to begin clinical trials
- Sputnik V: RDIF to manufacture 100 million doses
- ISSAR pharma licenses its New Chemical Entities
- IDT Biologika agrees to produce Astra’s COVID vaccine
- Pfizer’s COVID–19 vaccine update